

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

PROFIT WARNING

This announcement is made by Aceso Life Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended 31 March 2024 (“**Reporting Period**”) and information currently available to the Board, the Group is expected to record a loss for the Reporting Period of approximately HK\$869 million, as compared to the loss of approximately HK\$208 million for the corresponding period in 2023. The increase in the Group’s loss is mainly attributable to the (i) increase in fair value losses on financial assets at FVTPL (ii) increase in fair value losses on financial liabilities at FVTPL; (iii) increase in share of loss of associate company; (iv) increase in fair value losses on investment properties.

The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group for the Reporting Period and the information available to date, but not based on any data or information reviewed by the independent auditor or audit committee of the Company. The Company is still in the process of preparing and finalising the Group's unaudited consolidated results for the Reporting Period and the information may be subject to adjustments. Details of the Group's financial results and performance for the Reporting Period will be disclosed in the annual results announcement of the Company which is expected to be announced in late June 2024.

Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the shares or other securities of the Company.

By order of the Board
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

Hong Kong, 18 June 2024

As at the date of this announcement, the Board comprises two executive directors, namely Mr. Fok Chi Tak and Dr. Zhiliang Ou, J.P. (Australia); and three independent non-executive directors, namely Mr. Mak Yiu Tong, Mr. Lam Kwan Sing and Mr. Chan Ming Sun Jonathan.